Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test for Chagas’ Diseaseclinical trials of the company's new confirmatory test for Chagas’ disease, a serious and potentially fatal parasitic infection.
Chagas' disease is endemic in large parts of Latin America, where it affects up to 11 million people, and has emerged in the U.S., where more than 300,000 people are infected, according to the Centers for Disease Control and Prevention. The disease is difficult to diagnose, and is often silent for years before clinical symptoms appear. During this time, carriers can pass on the parasite through blood donations and infect transfusion recipients.
Existing screening tests that detect antibodies to the parasite are frequently inaccurate. A complex method called radioimmunoprecipitation (RIPA) is sometimes used to confirm screening test results, but is beyond the reach of most laboratories. There are no FDA-approved confirmatory test methods.
Immunetics’ test, called an immunoblot, detects antibodies to the parasite and is based on the same technology used in confirmatory tests for HIV and several other bloodborne infections. Data presented by Immunetics at meetings in 2010 of the American Association of Blood Banks and the American Society of Tropical Medicine and Hygiene showed the immunoblot test to be as accurate as RIPA in preliminary studies, said Dr. Andrew Levin, president and scientific director, Immunetics.
"The new NIH grant will enable Immunetics to undertake a full-scale clinical trial to obtain data to submit to the FDA for approval of the immunoblot as a confirmatory test. Immunetics will undertake the studies with collaborators at Blood Systems Research Institute, the American Red Cross, and the Centers for Disease Control and Prevention," Levin said.
“This grant award gives us the opportunity to take our Chagas’ immunoblot test through the clinical studies needed to establish its validity as a confirmatory test. We are very grateful for NIH support for this project, which will allow us to bring forward a practical solution to one part of the growing public health and blood safety problem that Chagas’ disease presents in the U.S. and Latin America," he said.
About Immunetics, Inc.
Immunetics Inc., (http://www.immunetics.com) offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over 10 years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is better, cost-efficient care through more accurate diagnosis. Immunetics is headquartered in Boston, Mass. Follow Immunetics on Twitter at http://twitter.com/immunetics.
Immunetics, 27 Drydock Ave., Boston, Massachusetts 02210
Press Contact: Don Goncalves, Tiziani Whitmyre, 781-793-9380, firstname.lastname@example.org
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test for Chagas’ Disease here
News-ID: 173535 • Views: 1527
More Releases from Immunetics
Immunetics Receives $500,000 from Massachusetts Life Sciences Center to Commerci …
Immunetics, Inc., today announced it has been awarded a $500,000 Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) to commercialize its BacTx® rapid test for detecting bacterial contamination in platelets. Platelets are a vital blood product enabling clotting, and patients suffering from trauma, surgical procedures, cancer, or chemotherapy must receive platelet transfusions to survive. Bacterial contamination of platelets is the leading cause of infection during transfusion, with patients facing the